Background: Molecular testing of thyroid fine-needle aspirates has demonstrated value in cases
| INTRODUCTION
While thyroid nodules are quite common, only about 8%-15% are found to be histologically malignant. 1, 2 Regardless, thyroid carcinoma is one of the most common endocrine malignancies. (B-VI) malignant. 6 According to NCCN guidelines, repeat biopsy is recommended for the solid lesions with nondiagnostic cytology, observation is recommended for the nodules of stable size with benign cytology, molecular diagnostic analysis is recommended for consideration in the indeterminate nodules (AUS/FLUS, FN/SFN), and surgery is recommended for aspirates that are diagnosed as carcinoma or suspicious for carcinoma. 7 Commercially available testing options for molecular analysis of nodules with the indeterminate cytology include a messenger-RNA gene expression classifier designed to define benign status of the nodule, 1 a microRNA expression classifier, 8 a Next Generation Sequencing (NGS) based oncogene panel also incorporating relevant RNA fusions and translocation, 9, 10 and a combination test based upon NGS-based mutational analysis and a microRNA expression based classifier ( Figure 1 ). 11, 12 Many current molecular tests that amplify nucleic acid can now be performed on extremely small amounts of tumor specimen including cytology smears prepared from fine-needle aspirates. Molecular testing of cytology smears can also be focused to specific areas of morphologic concern through targeted microdissection which can enrich the desired cell population for molecular analysis. [13] [14] [15] Based on well-known sample adequacy variation between fine needle passes, this technique of targeted microdissection can ensure molecular analysis of the actual diagnostic cells of concern.
The taking of a separate dedicated needle aspiration pass solely for molecular testing runs the risk that without microscopic confirmation, thyroid follicular cell adequacy cannot be assured. Molecular testing of cytology smears can therefore increase the diagnostic yield from FNA procedures, potentially eliminating the need for repeat biopsy in certain cases. Furthermore, slides offer the opportunity to perform clinical retrospective studies using archived materials. Comparative molecular analysis of archival slide format testing also affords the chance to understand the temporal sequence of molecular change over time.
The purpose of this study was to demonstrate the accuracy and potential utility of combined molecular analysis (mutational profiling and microRNA classifier status using ThyGenX and ThyraMIR tests) of FNA cytology smears. We compared molecular test results of cytology smears to that of preserved RNA from an FNA sample collected from the same patient, same nodule, during the same FNA procedure.
| MATERIALS AND METHODS

| Specimen collection
Two sets of samples were used in this study. The first set of samples was analyzed to determine whether molecular testing can be carried out from FNA smears. For this, total cytology specimen was scrapped (macrodissection) for the isolation of total nucleic acid (TNA) as explained below. The second set of samples was retrospectively evaluated to test our ability to apply the approach of targeted microdissection for molecular testing.
The first set of samples was collected as part of a prospective study approved by the Chesapeake Institutional Review Board (Approval # 00009811) and informed consent was obtained from study participants.
A random subset of 47 patient specimens collected during the first study that included matched FNA samples of cytology slide smears (airdried Diff-Quik or alcohol-fixed Pap) and RNA preserved (RNARetain, Asuragen) aspirates were evaluated. For these samples, the first drop of the FNA biopsy material was placed onto a slide, smeared and air-dried, and the remaining material was rinsed into RNA preservative solution.
The second set of samples was comprised of 22 retrospective, deidentified cytology smears, with histological diagnosis of dissected tumors, which were also evaluated to determine the suitability of cytology smears for diagnostic molecular analysis of thyroid FNA.
| TNA isolation from RNA preserved FNA
TNA was isolated from RNA preserved FNA using the phenolchloroform method. 16 
| TNA isolation from macrodissected FNA smears
All microscopic slides underwent whole slide imaging (Leica). Coverslips were removed by immersing in xylene (Fisher) for 48-72 hours. 13 Once the coverslips were off, slides were washed in xylene followed by a wash with 80% ethanol and air-dried. 17 Slides were then moistened using a drop of Tris-Tween buffer (10 mM Tris pH 8.0, 0.05% Tween 20) and all FNA smear material was scraped into RNA Retain (Asuragen), followed by TNA isolation using the phenol-chloroform method. according to manufacturer's instructions.
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FIGURE 1 ThyGenX and ThyraMIR panel designs. ThyGenX oncogene panel interrogates 9 hotspot regions in the BRAF, HRAS, KRAS, NRAS, and PIK3CA genes, 6 fusion transcripts, which play a role in thyroid tumorigenesis. ThyraMIR assay is a proprietary microRNA expression-based algorithm to classify the risk of malignancy in thyroid nodules
| Next generation mutational sequencing (ThyGenX) test
Detailed procedures for the NGS-based mutational sequencing have been previously described. 12, 18 Briefly, sample quality and copy number of extracted TNA were analyzed by qPCR analysis of LINE1 retrotransposons. The LINE1 copy number was used to determine optimal template inputs for multiplex Polymerase Chain Reaction (PCR). 12, 18 RNA component of TNA was reverse transcribed, and the sequencing libraries were prepared using a multiplex gene-specific PCR with the DNA and the cDNA components of the TNA. Amplified gene products were then bar-coded using primers containing custom molecular barcodes. Libraries were purified using AxyGen mag prep kit (Corning) and quantitated using Illumina Library Quant Kit (KAPA). Finally, an 
| MicroRNA expression classifier (ThyraMIR) test
The ThyraMIR test was used to provide the microRNA classifier status. 12 The microRNA component of TNA was converted to cDNA using miRCURY LNA Universal RT microRNA PCR kit (Exiqon) using 5 μL of the isolated TNA. cDNA products were diluted 1:100 and plated onto custom designed 384-well plates precoated with micro-RNA specific primers (Exiqon) along with PCR amplification reagents, and the qPCR was performed on an AB Quant Studio 6 (Applied Biosystems) using Exilent SYBR Green kit (Exiqon 
| Data analysis
All the samples in this study were evaluated using ThyGenX and ThyraMIR tests as described above. A positive call was assigned to samples positive for the presence of mutations by ThyGenX or positive based upon the established classifier threshold for ThyraMIR. In samples that were scored as negative on both the tests, a negative diagnostic call was made.
3 | RESULTS
| TNA isolation from cytology smear specimens
TNAs were isolated from FNA specimens in RNA preservative, macro- 
| Suitability of microdissection based molecular testing using archived cytology smears
A retrospective study using archived, de-identified cytology smears from thyroid nodule FNAs with known, de-identified surgical pathology outcomes was performed to evaluate clinical suitability for microdissection based molecular testing. Twenty-two cases were included of which 13 had benign and 9 had malignant pathology. Of these, 6 cases were classified as B II, 7 cases as B III, 4 cases as B IV, 2 cases as B V, and 3 cases as B VI cytology based on the Bethesda cytology classification system. In total 8/22 microdissected cytology smears harbored mutations, including 4 BRAF, 3 KRAS, and 1 HRAS mutation ( Figure 4A ), whereas microRNA expression results were positive in 10/22 tested cases ( Figure 4A,B) . The combination of mutation and microRNA analysis correctly identified 7/9 samples as malignant and 10/13 samples as benign.
3.4 | Quality metrics of data from sequencing and microRNA expression for FNA samples stored using RNA preservative, whole slide cytology smear, and targeted microdissected cytology smears
In order to ensure that cytology smears are suitable for clinical testing we compared various QC metrics that are monitored during routine clinical testing of FNA samples in RNA preservative to that of cytology smears. As a quality measure, both DNA and RNA panel libraries were prepared as 2 independent replicates for sequencing.
For NGS-based testing, metrics for coverage depth and read alignment were used as indicators of both DNA and RNA-Seq quality.
As shown in Figure 5A -D, the median coverage for the DNA panel Figure 5E shows the reliable detection of NRAS_Q61R across a range of variant allele frequency (%VAF) as low Figure 5F shows the detection the NCOA4_RET4 fusion reads across a range of dilutions.
For microRNA expression profiling, testing was also carried out as 2 technical replicates. 3.5 | Mutation and microRNA testing of cytology smears in cases where FNA in RNA preservative provided insufficient quantity of TNA for molecular analysis
During routine mutation and microRNA testing of FNA specimens, we occasionally found that total amount of nucleic acid (TNA) in the FNA in RNA preservative specimen was insufficient for molecular analysis.
We hypothesized that molecular testing of cytology smears could increase the diagnostic yield in such cases without requiring an additional FNA procedure. In total, 14 clinical cases that had limited nucleic acid in the RNA preserved FNA specimens were examined.
There was insufficient TNA present in 4/14 cases for mutation analysis and 14/14 cases for microRNA analysis (Table 1 ). All cases that initially had insufficient TNA in the original FNA specimen in RNA preservative had corresponding cytology smears that provided sufficient TNA for molecular analysis. In cases in which mutation analysis was originally assessable, mutation results of cytology smears were Consistently, when discordant results were found for the microRNA expression test, the microRNA coefficient for the FNA specimen in RNA preservative was in proximity to the threshold for a positive microRNA result whereas the coefficient for the cytology smears was above the threshold.
Importantly, metrics of data quality from cytology specimens were as robust as those used clinically for FNA specimens in RNA preservative. However, when we tested instances where the quality and quantity of nucleic acid derived from FNA's in RNA preservative was insufficient for molecular analysis, microdissection of cytology slide smears provided sufficiently high quantity and quality of nucleic acid for analysis. In these cases, molecular testing of microdissected cytology slides provided clinically meaningful results.
The ability to perform molecular analysis of microdissected cytology smears could minimize concern for sampling variation between needle passes. In this alternative approach, molecular testing of the microdissected cytology slide material can ensure molecular analysis of the same diagnostic cellular material used to render the cytology diagnosis. The obvious disadvantage is that the archived cytology slide material may be consumed for molecular analysis. In another scenario, initial molecular testing could be done using FNA in an RNA stabilizing buffer and the FNA on cytology smears could be used for additional testing in cases where initial molecular results do not correlate with the cytological results and other clinical findings.
Noteworthy issues, when employing ancillary molecular analysis, are sampling variation when the specimen is divided for separate testing and competition for representative material for optimal correlative interpretation. Slide-format sample procurement using microdissection has the advantage of using cytologic features to ensure optimal specimen division for molecular testing after microscopic assessment is based on the entire sample. Even with direct analysis of the needle aspirate, the requirements for both NGS sequencing analysis and micro-RNA profiling as quite low enabling the bulk of the aspirate to be used for cytology interpretation. Careful attention is required however when multiple needle aspiration passes are employed since individual needle passes are more likely to lead to sampling variation. Individual passes should be managed in a fashion that enables each part of each pass to contribute to both microscopic and molecular analysis.
In summary, we provide a comprehensive approach to maximize the diagnostic material of each individual FNA pass, offering options to carry out mutational and microRNA testing using FNA specimens either in RNA preservative fluid or on cytology slides, depending upon limiting factors. Furthermore, when molecular results from an FNA pass are insufficient or where more clarity is desired, we show that combination mutation and microRNA testing of cytology slides can to provide supplemental results for each FNA pass.
